Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glurenorm versus repaglinide in diabetic kidney disease with macroalbuminuria
ChiCTR-IPR-17012032Phase 4Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of gliquidone and repaglinide in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Changhai Hospital. Primary endpoints: Blood glucose level and Renal function. Planned start Sep 2017; status: not yet recruiting.
02
Drugs
gliquidonerepaglinide
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-IPR-17012032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012032.